Journal of Neurogastroenterology and Motility

The Korean Society of Neurogastroenterology and Motility (대한소화기 기능성질환 운동학회)
권호 표지
DOI QR코드

DOI QR Code

Randomized, Controlled, Multi-center Trial: Comparing the Safety and Efficacy of DA-9701 and Itopride Hydrochloride in Patients With Functional Dyspepsia

  • Received : 2014.10.08
  • Accepted : 2015.01.07
  • Published : 2015.07.30
⟨ Previous Next ⟩

Abstract

Background/Aims Therapies of functional dyspepsia (FD) are limited. DA-9701 is a novel prokinetic agent formulated with Pharbitis semen and Corydalis Tuber. We aimed to assess the efficacy of DA-9701 compared with itopride in FD patients. Methods Patients with FD randomly received either itopride 50 mg or DA-9701 30 mg t.i.d after a 2-week baseline period. After 4 weeks of treatment, 2 primary efficacy endpoints were analyzed: the change from baseline in composite score of the 8 dyspeptic symptoms and the overall treatment effect. Impact on patients' quality of life was assessed using the Nepean Dyspepsia Index (NDI) questionnaire. Results We randomly assigned 464 patients with 455 having outcome data. The difference of the composite score change of the 8 symptoms between the 2 groups was 0.62, indicating that DA-9701 was not inferior to itopride. The overall treatment effect response rate was not different between the groups. When responder was defined as ${\geq}5$ of the 7 Likert scale, responder rates were 37% of DA-9701 and 36% of itopride group. Patients receiving DA-9701 experienced similar mean percentage of days with adequate relief during the 4-week treatment period compared with those receiving itopride (56.8% vs 59.1%). Both drugs increased the NDI score of 5 domains without any difference in change of the NDI score between the groups. The safety profile of both drugs was comparable. Conclusions DA-9701 significantly improves symptoms in patients with FD. DA-9701 showed non-inferior efficacy to itopride with comparable safety.

Keywords

Acknowledgement

Supported by : Plant Diverse Research Center

References

  1. Lee YY, Chua AS. What indigestion means to the malays? J Neurogastroenterol Motil 2013;19:295-300. https://doi.org/10.5056/jnm.2013.19.3.295
  2. Tack J, Talley NJ, Camilleri M, et al. Functional gastroduodenal disorders. Gastroenterology 2006;130:1466-1479. https://doi.org/10.1053/j.gastro.2005.11.059
  3. Choi MG, Jung HK. Health related quality of life in functional gastrointestinal disorders in Asia. J Neurogastroenterol Motil 2011;17:245-251. https://doi.org/10.5056/jnm.2011.17.3.245
  4. Lee YY, Chua AS. Investigating functional dyspepsia in Asia. J Neurogastroenterol Motil 2012;18:239-245. https://doi.org/10.5056/jnm.2012.18.3.239
  5. Lee YY, Chua AS. Role of Helicobacter pylori in functional dyspepsia: more controversies than answers. J Neurogastroenterol Motil 2013;19:417. https://doi.org/10.5056/jnm.2013.19.3.417
  6. Moayyedi P, Soo S, Deeks J, et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev 2005;(2):CD002096.
  7. Lee TH, Choi JJ, Kim DH, et al. Gastroprokinetic effects of DA-9701, a new prokinetic agent formulated with Pharbitis Semen and Corydalis Tuber. Phytomedicine 2008;15:836-843. https://doi.org/10.1016/j.phymed.2008.02.019
  8. Lee TH, Son M, Kim SY. Effects of corydaline from Corydalis tuber on gastric motor function in an animal model. Biol Pharm Bull 2010;33:958-962. https://doi.org/10.1248/bpb.33.958
  9. Kim ER, Min BH, Lee SO, Lee TH, Son M, Rhee PL. Effects of DA-9701, a novel prokinetic agent, on gastric accommodation in conscious dogs. J Gastroenterol Hepatol 2012;27:766-772. https://doi.org/10.1111/j.1440-1746.2011.06924.x
  10. Choi S, Choi JJ, Jun JY, et al. Induction of pacemaker currents by DA-9701, a prokinetic agent, in interstitial cells of Cajal from murine small intestine. Mol Cells 2009;27:307-312. https://doi.org/10.1007/s10059-009-0039-6
  11. Cho YK, Choi MG, Kim SH, et al. [The effect of mosapride on quality of life in functional dyspepsia.] Korean J Gastroenterol 2004;43:160-167. [Korean].
  12. Talley NJ, Verlinden M, Jones M. Validity of a new quality of life scale for functional dyspepsia: a United States multicenter trial of the Nepean Dyspepsia Index. Am J Gastroenterol 1999;94:2390-2397. https://doi.org/10.1111/j.1572-0241.1999.01363.x
  13. Talley NJ, Haque M, Wyeth JW, et al. Development of a new dyspepsia impact scale: the Nepean Dyspepsia Index. Aliment Pharmacol Ther 1999;13:225-235. https://doi.org/10.1046/j.1365-2036.1999.00445.x
  14. Cho YK, Choi MG, Kim SH, et al. The effect of mosapride on quality of life in functional dyspepsia. Korean J Gastroenterol 2004;43:160-167.
  15. Takahashi N, Yokota T, Murofushi N, Tamura S. Structures of Gibberellins $A_{26}$ and $A_{27}$ in immature seeds of Pharbitis nil. Tetrahedron Lett 1969;10:2077-2080. https://doi.org/10.1016/S0040-4039(01)88089-8
  16. Lee SP, Lee KN, Lee OY, et al. Effects of DA-9701, a novel prokinetic agent, on phosphorylated extracellular signal-regulated kinase expression in the dorsal root ganglion and spinal cord induced by colorectal distension in rats. Gut Liver 2014;8:140-147. https://doi.org/10.5009/gnl.2014.8.2.140
  17. Lee TH, Kim KH, Lee SO, Lee KR, Son M, Jin M. Tetrahydroberberine, an isoquinoline alkaloid isolated from corydalis tuber, enhances gastrointestinal motor function. J Pharmacol Exp Ther 2011;338:917-924. https://doi.org/10.1124/jpet.111.182048
  18. Oh KH, Nam Y, Jeong JH, Kim IK, Sohn UD. The effect of DA-9701 on 5-hydroxytryptamine-induced contraction of feline esophageal smooth muscle cells. Molecules 2014;19:5135-5149. https://doi.org/10.3390/molecules19045135
  19. Min YW, Ko EJ, Lee JY, et al. Nitrergic pathway is the major mechanism for the effect of DA-9701 on the rat gastric fundus relaxation. J Neurogastroenterol Motil 2014;20:318-325. https://doi.org/10.5056/jnm13098
  20. Camilleri M, Bueno L, de Ponti F, Fioramonti J, Lydiard RB, Tack J. Pharmacological and pharmacokinetic aspects of functional gastrointestinal disorders. Gastroenterology 2006;130:1421-1434. https://doi.org/10.1053/j.gastro.2005.08.062
  21. Allescher HD, Wagner H. [STW 5/Iberogast: multi-target-action for treatment of functional dyspepsia and irritable bowel syndrome.] Wien Med Wochenschr 2007;157:301-307. [German]. https://doi.org/10.1007/s10354-007-0429-3
  22. Talley NJ, Tack J, Ptak T, Gupta R, Giguere M. Itopride in functional dyspepsia: results of two phase III multicentre, randomised, double-blind, placebo-controlled trials. Gut 2008;57:740-746. https://doi.org/10.1136/gut.2007.132449
  23. Ang D, Talley NJ, Simren M, Janssen P, Boeckxstaens G, Tack J. Review article: endpoints used in functional dyspepsia drug therapy trials. Aliment Pharmacol Ther 2011;33:634-649. https://doi.org/10.1111/j.1365-2036.2010.04566.x
  24. Design of Treatment Trials Committee, Irvine EJ, Whitehead WE, et al. Design of treatment trials for functional gastrointestinal disorders. Gastroenterology 2006;130:1538-1551. https://doi.org/10.1053/j.gastro.2005.11.058
  25. Matsueda K, Hongo M, Ushijima S, Akiho H. A long-term study of acotiamide in patients with functional dyspepsia: results from an open-label phase III trial in Japan on efficacy, safety and pattern of administration. Digestion 2011;84:261-268. https://doi.org/10.1159/000332404
  26. Chey WD, Howden CW, Tack J, Ligozio G, Earnest DL. Longterm tegaserod treatment for dysmotility-like functional dyspepsia: results of two identical 1-year cohort studies. Dig Dis Sci 2010;55:684-697. https://doi.org/10.1007/s10620-009-1049-0
  27. Jones M, Talley NJ. Minimum clinically important difference for the Nepean Dyspepsia Index, a validated quality of life scale for functional dyspepsia. Am J Gastroenterol 2009;104:1483-1488. https://doi.org/10.1038/ajg.2009.136

Cited by

  1. Effect of DA-9701 on Gastric Motor Function Assessed by Magnetic Resonance Imaging in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled Trial vol.10, pp.9, 2015, https://doi.org/10.1371/journal.pone.0138927
  2. Effect of DA-9701 on the Normal Motility and Clonidine-induced Hypomotility of the Gastric Antrum in Rats vol.22, pp.2, 2016, https://doi.org/10.5056/jnm15131
  3. Efficacy of DA-9701 (Motilitone) in Functional Dyspepsia Compared to Pantoprazole: A Multicenter, Randomized, Double-blind, Non-inferiority Study vol.22, pp.2, 2016, https://doi.org/10.5056/jnm15178
  4. Diagnosis and treatment of functional dyspepsia vol.59, pp.4, 2015, https://doi.org/10.5124/jkma.2016.59.4.311
  5. Analgesic Herbs vol.23, pp.6, 2015, https://doi.org/10.1089/act.2017.29135.eya
  6. DA‐9701 improves colonic transit time and symptoms in patients with functional constipation: A prospective study vol.32, pp.12, 2015, https://doi.org/10.1111/jgh.13807
  7. Efficacy and safety of manual acupuncture manipulations with different frequencies on epigastric pain syndrome (EPS) in functional dyspepsia (FD) patients: study protocol for a randomized controlled t vol.18, pp.1, 2015, https://doi.org/10.1186/s13063-017-1845-3
  8. Guideline Recommendation for Endpoints Used in Clinical Trials for Functional Dyspepsia vol.72, pp.4, 2015, https://doi.org/10.4166/kjg.2018.72.4.170
  9. Effect of DA-9701 on Feeding Inhibition Induced by Acute Restraint Stress in Rats vol.18, pp.1, 2015, https://doi.org/10.7704/kjhugr.2018.18.1.50
  10. DA-9701 (Motilitone): A Multi-Targeting Botanical Drug for the Treatment of Functional Dyspepsia vol.19, pp.12, 2015, https://doi.org/10.3390/ijms19124035
  11. Pharmacological treatments for functional nausea and functional dyspepsia in children: a systematic review vol.11, pp.12, 2015, https://doi.org/10.1080/17512433.2018.1540298
  12. Prokinetics for Functional Dyspepsia: A Systematic Review and Meta-Analysis of Randomized Control Trials vol.114, pp.2, 2019, https://doi.org/10.1038/s41395-018-0258-6
  13. Efficacy of Weikang Pian in Patients with Functional Dyspepsia: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial vol.2019, pp.None, 2015, https://doi.org/10.1155/2019/4827046
  14. A Randomized Double-blind Comparative Study of the Efficacy of Helicobacter pylori Eradication Therapy and Motilitone® for Functional Dyspepsia vol.19, pp.2, 2015, https://doi.org/10.7704/kjhugr.2019.19.2.106
  15. Effect of DA-9701 on the Gastrointestinal Motility in the Streptozotocin-Induced Diabetic Mice vol.10, pp.22, 2015, https://doi.org/10.3390/jcm10225282